Highlights the risk of persistent HEV infection transmitted via blood transfusion in immunosuppressed patients.
Answers are grounded in this paper and cite their sources.
May warrant HEV RNA screening in immunosuppressed transfusion recipients; case report leaves open need for prevalence studies.
AIM: With advent of reverse-transcription (RT)/polymerase chain reaction (PCR) for detection of the hepatitis E viral genome, we carried out retrospective examinations. METHODS: Serum samples collected from 68 patients diagnosed as viral hepatitis with unknown etiology were tested for viral markers of hepatitis virus. RESULTS: Two of them were found positive for hepatitis E viral RNA. While the clinical course of one patient (patient 1) was typical as acute hepatitis E, another patient (patient 2) was persistently infected with HEV. Patient 2 was infected with the virus via blood transfusion during chemotherapy against T-cell lymphoma. The entire viral genome from the donor was identical with that from the serum of patient 2 obtained on day 170 after the transfusion of the implicated red blood cell (RBC) product, confirming the transmission of HEV by transfusion. The patient remained negative for anti-HEV antibodies for the follow-up period of six months, probably due to immune suppression by lymphoma and chemotherapy. CONCLUSION: We report here an unusual case of long-term HEV infection in a patient with T-cell lymphoma. Persistent infection with HEV was probably due to the absence of anti-HEV antibodies, which was caused by lymphoma and chemotherapy.
No takes yet. Share an insight, caveat, or question.
Tamura et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: